Evidence map›Paper›PMID 36537564›Full record

ArticleCell transplantation

Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation.

Ryo Maemura, Manabu Wakamatsu, Kana Matsumoto, Hirotoshi Sakaguchi, Nao Yoshida, Asahito Hama, Taro Yoshida, Shunsuke Miwata, Hironobu Kitazawa, Kotaro Narita and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Ryo MaemuraDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-1307-4378
Manabu WakamatsuDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kana MatsumotoDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
Hirotoshi SakaguchiDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Nao YoshidaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Asahito HamaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Taro YoshidaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shunsuke MiwataDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hironobu KitazawaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kotaro NaritaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shinsuke KataokaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Daisuke IchikawaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Motoharu HamadaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Rieko TaniguchiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kyogo SuzukiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nozomu KawashimaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-5700-4481
Eri NishikawaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Atsushi NaritaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yusuke OkunoCenter for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Nobuhiro NishioDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Koji KatoDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.
Seiji KojimaDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kunihiko MoritaDepartment of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.
Hideki MuramatsuDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yoshiyuki TakahashiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPDoshisha Women's College of Liberal Arts · JPNagoya University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melphalan is widely used for hematopoietic stem cell transplantation (HSCT) conditioning. However, the relationship between its pharmacokinetic (PK) and transplantation outcomes in children has not been thoroughly investigated. We prospectively analyzed the relationship between melphalan area under the curve (AUC) and transplantation outcome and examined the development of a predictive model for melphalan clearance in children. This study included 43 children aged 0 to 19 years who underwent HSCT following a melphalan-based conditioning regimen from 2017 to 2021. In univariable analysis, high-melphalan AUC resulted in a significantly lower cumulative incidence of acute graft-versus-host disease and a higher cumulative incidence of thrombotic microangiopathy, although no significant difference was observed in survival. Regression analysis of a randomly selected derivation cohort (

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationChildCreatinineHumansMelphalanTransplantation ConditioningCreatinineMelphalanchildrenhematopoietic stem cell transplantationmelphalan pharmacokineticsthrombotic microangiopathy

Identifiers

PMID36537564
PMCPMC9772935
OpenAlexW4312129547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.